- Home
- ARR vs HROW Comparison
ARR vs HROW Comparison
Compare ARR & HROW Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ARR
- HROW
- Stock Information
- Founded
- ARR 2008
- HROW 1998
- Country
- ARR United States
- HROW United States
- Employees
- ARR N/A
- HROW N/A
- Industry
- ARR Real Estate Investment Trusts
- HROW Biotechnology: Pharmaceutical Preparations
- Sector
- ARR Real Estate
- HROW Health Care
- Exchange
- ARR Nasdaq
- HROW Nasdaq
- Market Cap
- ARR 1.8B
- HROW 1.4B
- IPO Year
- ARR N/A
- HROW N/A
- Fundamental
- Price
- ARR $15.63
- HROW $42.00
- Analyst Decision
- ARR Buy
- HROW Strong Buy
- Analyst Count
- ARR 4
- HROW 7
- Target Price
- ARR $15.50
- HROW $68.50
- AVG Volume (30 Days)
- ARR 3.5M
- HROW 827.9K
- Earning Date
- ARR 10-22-2025
- HROW 11-12-2025
- Dividend Yield
- ARR 18.47%
- HROW N/A
- EPS Growth
- ARR N/A
- HROW N/A
- EPS
- ARR N/A
- HROW N/A
- Revenue
- ARR $20,589,000.00
- HROW $227,661,000.00
- Revenue This Year
- ARR $350.86
- HROW $43.92
- Revenue Next Year
- ARR $54.46
- HROW $41.32
- P/E Ratio
- ARR N/A
- HROW N/A
- Revenue Growth
- ARR N/A
- HROW 47.69
- 52 Week Low
- ARR $13.18
- HROW $20.85
- 52 Week High
- ARR $20.39
- HROW $59.23
- Technical
- Relative Strength Index (RSI)
- ARR 61.38
- HROW 46.09
- Support Level
- ARR $14.00
- HROW $46.45
- Resistance Level
- ARR $15.73
- HROW $48.79
- Average True Range (ATR)
- ARR 0.31
- HROW 2.49
- MACD
- ARR 0.15
- HROW -0.72
- Stochastic Oscillator
- ARR 96.42
- HROW 14.10
About ARR ARMOUR Residential REIT Inc.
ARMOUR Residential REIT Inc operate in the U.S. and invest in fixed rate residential, adjustable rate and hybrid adjustable rate residential MBS issued or guaranteed by U.S. GSEs or guaranteed by Ginnie Mae. It also invest in U.S. Treasury Securities and money market instruments.
About HROW Harrow Inc.
Harrow Inc is an eyecare pharmaceutical company engaged in the discovery, development, and commercialization of ophthalmic pharmaceutical products for the U.S. market. The company helps U.S. eyecare professionals preserve the gift of sight by making its comprehensive portfolio of prescription and non-prescription pharmaceutical products accessible and affordable to millions of Americans. Its operating segments are The Branded segment includes activities of the Company's FDA-approved ophthalmology pharmaceutical products, including the out-licensing of rights to certain of branded products; and The ImprimisRx segment represents activities in the Company's ophthalmology-focused pharmaceutical compounding business.